The George Institute For Global Health
Global
United Kingdom
India
China
Australia

News and Events

‘It is important to me to be a role model, an example of a strong resilient Aboriginal woman who can achieve anything she sets her mind to.’

Friend of The George Institute for Global Health, June Oscar AO (pictured above, right), will become Australia’s new Aboriginal and Torres Strait Islander Social Justice Commissioner starting in April.

Migraine sufferers are being invited to take part in the trial of a new treatment aimed at preventing these debilitating attacks.

Dr Kate Hunter, Senior Research Fellow in the Injury Division at The George Institute, has been awarded a prestigious Early-Mid Career Fellowship from NSW Health for her work in Aboriginal and Torres Strait Islander health.

Media release: 
02/02/2017

Commonly used non-steroidal anti-inflammatory drugs used to treat back pain provide little benefit, but cause side effects, according to new research from The George Institute for Global Health.

Media release: 
02/02/2017

The George Institute’s FoodSwitch program has been selected to participate in LAUNCH Food – a global challenge to improve health outcomes by enabling people to make healthy food choices.

Media release: 
30/01/2017

Statement from Professor Vlado Perkovic, Executive Director, The George Institute Australia:
 

Media release: 
30/01/2017

Today marks the official release of the report, ‘Low Vision, quality of life and independence: A review of the evidence on aids and technologies’ by Macular Disease Foundation Australia produced in collaboration with The George Institute for Global Health.

Media release: 
27/01/2017

The George Institute for Global Health and the University of New South Wales (UNSW) today announced their intention to form a strategic collaboration to bolster high-impact medical research and transform lives around the world, a priority of both organisations.

Type 2 diabetes often causes damaging effects to the kidneys, sometimes resulting in the need for dialysis or kidney transplantation. The ongoing CANVAS-R trial is testing whether canagliflozin -- a member of a new class of diabetes treatments known as sodium glucose co-transporter 2 (SGLT2) inhibitors -- can slow kidney function decline and provide other benefits to diabetic patients.

Pages